Oncolytic Virus Therapy Market Study Highlights How Industry Demand Is Evolving

The oncolytic virus therapy sector is emerging as a rapidly advancing field with promising potential for cancer treatment. Driven by technological innovations and increasing clinical adoption, this market is set to experience substantial growth in the coming years. Let's explore the market's expected size, the companies leading its development, key trends shaping its trajectory, and the main segments defining its structure.

Projected Growth Trajectory and Market Size of Oncolytic Virus Therapy
The oncolytic virus therapy market is on track for remarkable expansion, anticipated to reach a valuation of $0.68 billion by 2030. This growth represents a compound annual growth rate (CAGR) of 23.7%, highlighting the sector's fast-paced development. Key factors contributing to this surge include rising demand for genetically engineered oncolytic viruses, increased usage in treating lung, prostate, and brain cancers, growth of specialized clinics and hospitals offering virotherapy, and stronger investment in combination and novel virus therapies. Additionally, the expansion of clinical trial infrastructure in emerging markets supports this upward trend. Notable market drivers also involve the integration of AI and big data in research, the use of genomics and precision medicine to tailor therapies, deployment of digital platforms for clinical trial monitoring, automation in virus manufacturing and quality control, and IoT-enabled tracking for virus storage and distribution.

The oncolytic virus therapy market size has grown exponentially in recent years. It will grow from $0.23 billion in 2025 to $0.29 billion in 2026 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to development of hsv- and adenovirus-based oncolytic therapies, early clinical trials in melanoma and breast cancer, growing interest from cancer research institutes, increasing government funding for virotherapy research, rising collaborations between biotech companies and academic institutions.

Download a free sample of the oncolytic virus therapy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Organizations Influencing the Oncolytic Virus Therapy Market
Several prominent companies are actively shaping the oncolytic virus therapy space, including Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, and KaliVir Immunotherapeutics Inc. Among recent developments, in February 2025, UroGen Pharma Ltd., a biotechnology firm with roots in the US and Israel, acquired assets related to the oncolytic virus ICVB-1042 from IconOVir Bio, Inc. This move aims to bolster UroGen's therapy pipeline and enhance its immunotherapy technologies, particularly targeting bladder cancer and other locally treated malignancies. IconOVir Bio specializes in next-generation oncolytic viruses designed to selectively destroy cancer cells while stimulating immune responses.

Regulatory Approvals and Their Role in Oncolytic Virus Therapy Expansion
A significant focus within the oncolytic virus therapy industry is the pursuit of regulatory approvals to fast-track innovative cancer treatments. These approvals, granted by health authorities, ensure that new therapies meet safety and efficacy standards before entering the market. For example, in March 2024, ImmVira, a Chinese biotechnology company, earned Fast Track designation from the FDA for its therapy MVR-T3011 IT. This treatment targets recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who progressed after platinum-based chemotherapy and prior anti-PD-1/PD-L1 treatments. The Fast Track status is designed to speed up the development and review process for therapies addressing serious conditions with unmet medical needs, underscoring the urgency and promise seen in this field.

View the full oncolytic virus therapy market report:
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Market Segments Defining the Oncolytic Virus Therapy Industry
This market is segmented in several critical ways to cover a broad spectrum of therapies and applications:
1) Therapy Type: including Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), and other therapy types.
2) Virus Type: divided into genetically engineered oncolytic viruses and oncolytic wild-type viruses.
3) Application Areas: spanning breast cancer, lung cancer, prostate cancer, melanoma, brain tumors, and blood cancers.
4) End-User Categories: such as hospitals, specialty clinics, and cancer research institutes.

Further breakdown of therapy types reveals subcategories like genetically modified HSV oncolytic viruses, T-VEC therapy, combination HSV therapies, conditionally replicating adenoviruses, oncolytic adenovirus immunotherapies, therapies involving reovirus and genetically engineered variants, poxvirus-based treatments, and approaches using Newcastle Disease Virus in both wild-type and modified forms. Other emerging therapies include measles virus-based treatments, vesicular stomatitis virus (VSV) therapies, and experimental oncolytic virus platforms that continue to broaden the therapeutic landscape.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.